On February 6, 2020 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in the BIO CEO & Investor Conference being held at the Marriott Marquis in New York, February 10-11, 2020 (Press release, ProMIS Neurosciences, FEB 6, 2020, View Source [SID1234553917]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ProMIS’ Executive Chairman, Eugene Williams will provide a brief update on the company and present supportive data for the Company’s antibody programs targeting neurodegenerative diseases. Mr. Williams’ presentation is scheduled for February 11, 2020 at 3:00 pm ET. Webcasting is not available for this event.